Project Details
Description
A Phase 1, Open-Label, Dose-Escalation Study of Olaratumab as a Single Agent and in Combination with Doxorubicin, Vincristine/Irinotecan, or High-Dose Ifosfamide in Pediatric Patients with Relapsed or Refractory Solid Tumors (I5B-MC-JGDN)
| Status | Finished |
|---|---|
| Effective start/end date | 12/22/15 → 12/22/20 |
Funding
- ELI LILLY AND COMPANY
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.